Segment and Geographic Information

6 Months Ended

Dec. 31, 2015

Segments and Geographic Information [Abstract]

Segment and Geographic Information

SEGMENT AND GEOGRAPHIC INFORMATION

As discussed in Note 1, we have the following reportable segments: Consumer Healthcare, Branded Consumer Healthcare, Prescription Pharmaceuticals, Specialty Sciences, and Other. The accounting policies of each segment are the same as those described in Note 1. The majority of corporate expenses, which generally represent shared services, are charged to operating segments as part of a corporate allocation. Unallocated expenses relate to certain corporate services that are not allocated to the segments.

We generated third-party net sales in the following geographic locations⁽¹⁾ during each of the periods presented below (in millions):

	Six Months Ended		Fiscal Year Ended
	December 31, 2015		June 27, 2015		June 28, 2014		June 29, 2013
Ireland	$	177.8	$	344.0	$	146.7	$	—
U.S.	1,695.1		3,303.6		3,291.6		2,978.1
Europe	720.1		613.6		217.2		164.0
All other countries(2)	176.5		342.7		405.3		397.7
	$	2,769.5	$	4,603.9	$	4,060.8	$	3,539.8

⁽¹⁾We attribute net sales to countries based on sales location.

⁽²⁾Includes sales generated primarily in Israel, Mexico, Australia, and Canada.

The net book value of property and equipment by location was as follows (in millions):

	December 31, 2015		June 27, 2015		June 28, 2014
Ireland	$	1.3	$	1.4	$	2.0
U.S.	555.0		558.6		530.7
Europe	157.2		153.8		31.7
Israel	115.7		119.8		119.6
All other countries	57.0		98.8		95.9
	$	886.2	$	932.4	$	779.9

Sales to Walmart accounted for 13% of consolidated net sales for the six months endedDecember 31, 2015 and 15%, 19%, and 19% for the fiscal years endedJune 27, 2015, June 28, 2014, and June 29, 2013. Sales to Walmart are reported primarily in our CHC segment.

Below is a summary of our results by reporting segment (in millions):

	CHC			BCH (1)			Rx			Specialty Sciences (2)			Other			Unallocated			Total(3)
Six Months Ended December 31, 2015
Net sales	$	1,384.7		$	627.9		$	543.4		$	168.4		$	45.1		$	—		$	2,769.5
Operating income (loss) (4)	$	209.2		$	(155.3	)	$	195.3		$	15.8		$	(19.5	)	$	(151.0	)	$	94.5
Operating income (loss) %	15.1		%	(24.7		)%	35.9		%	9.4		%	(43.3		)%	—		%	3.4		%
Total assets	$	4,007.8		$	6,324.0		$	3,015.5		$	5,833.5		$	213.1		$	—		$	19,393.9
Capital expenditures	$	45.2		$	18.4		$	12.8		$	—		$	1.4		$	—		$	77.8
Property and equip, net	$	586.5		$	123.4		$	129.0		$	—		$	47.3		$	—		$	886.2
Depreciation/amortization	$	66.8		$	66.5		$	43.8		$	145.6		$	5.3		$	—		$	328.0
Fiscal Year Ended June 27, 2015
Net sales	$	2,750.0		$	401.1		$	1,001.1		$	344.0		$	107.7		$	—		$	4,603.9
Operating income (loss)	$	405.6		$	26.6		$	373.9		$	36.3		$	26.8		$	(121.5	)	$	747.7
Operating income (loss) %	14.7		%	6.6		%	37.3		%	10.6		%	24.9		%	—		%	16.2		%
Total assets	$	4,381.6		$	6,441.1		$	2,667.9		$	5,979.0		$	251.0		$	—		$	19,720.6
Capital expenditures	$	80.5		$	3.6		$	42.9		$	0.5		$	6.4		$	3.1		$	137.0
Property and equip, net	$	600.0		$	122.5		$	124.1		$	—		$	85.8		$	—		$	932.4
Depreciation/amortization	$	123.2		$	38.3		$	85.1		$	291.6		$	10.6		$	—		$	548.8
Fiscal Year Ended June 28, 2014
Net sales	$	2,849.4		$	—		$	927.1		$	146.7		$	137.6		$	—		$	4,060.8
Operating income (loss)	$	413.1		$	—		$	349.8		$	(68.6	)	$	46.1		$	(173.4	)	$	567.0
Operating income (loss) %	14.5		%	—		%	37.7		%	(46.7		)%	33.5		%	—		%	14.0		%
Total assets	$	4,931.0		$	—		$	2,537.2		$	6,096.6		$	288.0		$	—		$	13,852.8
Capital expenditures	$	128.3		$	—		$	32.9		$	—		$	10.4		$	—		$	171.6
Property and equip, net	$	577.3		$	—		$	104.8		$	2.1		$	95.7		$	—		$	779.9
Depreciation/amortization	$	106.6		$	—		$	86.5		$	154.4		$	11.4		$	—		$	358.9
Fiscal Year Ended June 29, 2013
Net sales	$	2,671.0		$	—		$	709.5		$	—		$	159.3		$	—		$	3,539.8
Operating income (loss)	$	401.8		$	—		$	263.2		$	—		$	48.9		$	(34.7	)	$	679.1
Operating income (loss) %	15.0		%	—		%	37.1		%	—		%	30.7		%	—		%	19.2		%
Total assets	$	3,447.5		$	—		$	1,604.9		$	—		$	284.5		$	—		$	5,336.9
Capital expenditures	$	97.1		$	—		$	17.7		$	—		$	17.3		$	—		$	132.2
Property and equip, net	$	508.0		$	—		$	80.8		$	—		$	92.7		$	—		$	681.4
Depreciation/amortization	$	96.1		$	—		$	54.9		$	—		$	9.1		$	—		$	160.2

⁽¹⁾     BCH includes activity subsequent to March 30, 2015.

⁽²⁾    Specialty Sciences includes activity subsequent to December 18, 2013.

⁽³⁾Amounts may not cross-foot due to rounding.    

⁽⁴⁾      The BCH segment operating loss included a $185.1 million impairment charge on indefinite-lived intangible assets purchased in conjunction with the Omega acquisition (See Note 3 for more information). The Other operating loss included a $29.0 million impairment charge related to our India API held for sale assets (See Note 9 for more information).

The following is a summary of our net sales by category (in millions):

	Six Months Ended		Fiscal Year Ended
	December 31, 2015		June 27, 2015		June 28, 2014		June 29, 2013
CHC
Cough/Cold/Allergy/Sinus(1)	$	259.2	$	486.2	$	510.1	$	500.6
Analgesics(1)	200.3		441.7		504.0		536.0
Gastrointestinal(1)	204.2		395.3		400.1		388.8
Infant nutritionals	200.2		383.9		374.8		350.1
Smoking cessation	159.7		299.4		236.8		193.2
Vitamins, minerals and dietary supplements(1)	110.6		185.6		176.9		158.3
Animal health	62.3		156.9		178.0		123.2
Other CHC(1),(2)	188.2		401.0		468.7		420.9
Total CHC	1,384.7		2,750.0		2,849.4		2,671.1
BCH branded OTC products	627.9		401.1		—		—
Generic prescription drugs	543.4		1,001.1		927.1		709.5
Tysabri® royalties	168.4		344.0		146.7		—
Active pharmaceutical ingredients	45.1		107.7		137.6		159.3
Total net sales	$	2,769.5	$	4,603.9	$	4,060.8	$	3,539.8

⁽¹⁾Includes sales from our OTC contract manufacturing business.

⁽²⁾  Consists primarily of feminine hygiene, diabetes care, dermatological care, diagnostic products, and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the CHC segment.